In-Silico Design and Study of Novel Tetrahydro-β-Carbolines as Inhibitor of HIV-1 Reverse Transcriptase

Authors

  • Sankaranarayanan Murugesan Associate Professor, Department of Pharmacy, Birla Institute of Technology and Science
  • Ashok Penta Associate Professor, Department of Pharmacy, Birla Institute of Technology and Science
  • Subhash Chander Associate Professor, Department of Pharmacy, Birla Institute of Technology and Science

Abstract

In the present study, we have designed 50 novel tetrahydro-β-carboline derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Docking studies of designed analogs were performed by molecular modeling software AutoDock 4.2 using HIV-1 reverse transcriptase (PDB ID: 1RT2) as receptor. Lipinski rule of five parameters and toxicity parameters were derived through online servers Molinspiration and Osiris property explorer respectively. Docking parameters such as binding free energy and predicted inhibitory constant (Ki) values of designed analogs were compared with standard drug Efavirenz and TNK-651. Among the designed analogs, TBB-III-29, TBB-III-33, TBB-III-39, TBB-III-42, TBB-III-44, TBB-III-45, TBB-III-46, TBB-III-49 and TBB-III-50 showed significant binding free energy and predicted inhibitory constants with that of standard drug Efavirenz and TNK-651. These results also indicate that, the designed analogs adopt a similar orientation and share the same binding mode as that of some classical non-nucleoside reverse transcriptase inhibitors (NNRTIs) within the active site of non-nucleoside inhibitory binding pocket (NNIBP) of HIV-1 reverse transcriptase.

 

Keywords: AIDS, HIV-1 reverse transcriptase, docking, molecular properties, tetrahydro-β-carboline

Cite this Article

Ashok Penta, Subhash Chander, Sankaranarayanan Murugesan. In-Silico Design and Study of Novel Tetrahydro-β-Carbolines as Inhibitor of HIV-1 Reverse Transcriptase. Research & Reviews: A Journal of Drug Design & Discovery. 2016; 3(1): 19–30p.

Downloads

Published

2019-03-19

Issue

Vol. 3 No. 1 (2016)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.